Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
10(4):1960-1969
InChi: InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4
PC3 and MES-SA at a dose of 10-20 mg/kg
Smiles: CN1CCN(CC2C=CC(=CC=2)C(=O)NC2=CC(NC3=NC(=CS3)C3=CN=CC=C3)=C(C)C=C2)CC1
LW8 demonstrated strong anti-tumor efficacy in vivo and caused a decrease in HIF-1alpha expression in frozen-tissue immunohistochemical staining
VX-770 Size:2mg solid 10(4):1960-1969VX 770, is a drug used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 45% cases of cystic fibrosis, and is included in a combination drug, lumacaftor ivacaftor, which is used to treat people with cystic fibrosis who have the F508del mutation in CFTR. Ivacaftor is a "potentiator" of CFTR, meaning it increases the probability that the defective channel